.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Cipla
Chinese Patent Office
Queensland Health
Boehringer Ingelheim
Harvard Business School
Novartis
Cantor Fitzgerald
Covington
Accenture

Generated: September 23, 2017

DrugPatentWatch Database Preview

NEXAVAR Drug Profile

« Back to Dashboard

What is the patent landscape for Nexavar, and what generic Nexavar alternatives are available?

Nexavar is a drug marketed by Bayer Hlthcare and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-four patent family members in fifty-four countries.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sorafenib tosylate profile page.

Summary for Tradename: NEXAVAR

Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list84
Clinical Trials: see list275
Patent Applications: see list4
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NEXAVAR at DailyMed

Pharmacology for Tradename: NEXAVAR

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► Subscribe ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► Subscribe ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► SubscribeY ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► Subscribe ► Subscribe
Bayer Hlthcare
NEXAVAR
sorafenib tosylate
TABLET;ORAL021923-001Dec 20, 2005RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NEXAVAR

Drugname Dosage Strength RLD Submissiondate
sorafenib tosylateTablets200 mgNexavar2/28/2014

Non-Orange Book Patents for Tradename: NEXAVAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,528,255Hydroxy, .omega.-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors► Subscribe
8,242,147Aryl ureas with angiogenisis inhibiting activity► Subscribe
7,928,239Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas► Subscribe
7,838,541Aryl ureas with angiogenesis inhibiting activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NEXAVAR

Country Document Number Estimated Expiration
Peru20422014► Subscribe
Canada2443952► Subscribe
Taiwan200626552► Subscribe
Japan2007302687► Subscribe
Japan3845792► Subscribe
Cyprus1114314► Subscribe
Spain2377847► Subscribe
Norway337326► Subscribe
Poland215029► Subscribe
Norway20013463► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NEXAVAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006008Lithuania► SubscribePRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
2007 00002Denmark► Subscribe
C 031/2006Ireland► SubscribeSPC 031/2006: 20070528, EXPIRES: 20210718
1140840/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
2006 008, C 1140840Lithuania► SubscribePRODUCT NAME: SORAFENIBAS IR FARMACINIU PO?I?RIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
280Luxembourg► Subscribe91280, EXPIRES: 20210720
5Finland► Subscribe
2006000059Germany► SubscribePRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
35/2006Austria► SubscribePRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON
2006008,C1140840Lithuania► SubscribePRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Fuji
Moodys
McKinsey
QuintilesIMS
Cipla
Queensland Health
Cantor Fitzgerald
Healthtrust
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot